**Multiple sclerosis phenotypes as a continuum: the role of neurological reserve**

Timothy Vollmer, MD,Kavita V. Nair, PhD, Ian M. Williams, PhD, Enrique Alvarez, MD

Department of Neurology (TV, KVN, EA), University of Colorado, and Rocky Mountain Multiple Sclerosis Center at the University of Colorado, Aurora, CO, USA; Department of Clinical Pharmacy (KVN), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Oxford PharmaGenesis (IMW), Oxford, UK.

**Corresponding author**

Professor Timothy Vollmer

Department of Neurology, University of Colorado School of Medicine, Academic Office 1, Mail Stop B-185, 12631 East 17th Avenue, Aurora, CO 80045, USA

Email: Timothy.Vollmer@ucdenver.edu

Published in*Neurology: Clinical Practice*

**Supplemental data**

* Supplementary table
* Supplementary references

**Supplementary Table.** Assessment measures for cognitive reserve and reserve-related patient characteristics

|  |  |
| --- | --- |
| **Concept** | **Potential measures** |
| **Reserve-building activities**  |  |
| * Past and current achievement
* Educational
* Occupational
 | * Assessments
* Sole-Padulles Childhood Enrichment measure
* Wechsler Abbreviated Scale of Intelligence – vocabulary subtest
* Occupational attainment
 |
| * Enrichment activities across a range of domains, including:
* cultural/intellectual
* physical
* communal
* spiritual/religious
 | * Patient-reported outcome measures:
* Stern Leisure Activities measure
* Godin Leisure-Time Exercise Questionnaire
* DeltaQuest Reserve-Building Activities measure
 |
| **Reserve-related person characteristics**  |  |
| * Attitudes, values and socio-emotional skills
 | * Person-reported measures of perseverance, work value and socio-emotional intelligence resources
* Measures of appraisal processes and personality
 |

**Supplementary references**

e1. Nakahara J, Maeda M, Aiso S, Suzuki N. Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy. Clin Rev Allergy Immunol 2012;42:26-34

e2. Wheeler MA, Clark IC, Tjon EC, et al. MAFG-driven astrocytes promote CNS inflammation. Nature 2020;578:593-599.

e3. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.

e4. Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol 2014;72 Suppl 1:1-5.

e5. Rice GPA, Kremenchutzky M, Cottrell DA, Baskerville J, Ebers GC. Observations from the natural history cohort of London, Ontario. In: Fililppi M, Comi G, editors. Topics in Neuroscience: Primary Progressive Multiple Sclerosis. Milan, Italy: Springer Verlag Italia; 2002.

e6. Kiselev I, Bashinskaya V, Baulina N, et al. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability. Mult Scler Relat Disord 2019;29:130-136.

e7. Lundstrom W, Greiner E, Lundmark F, et al. No influence on disease progression of non-HLA susceptibility genes in MS. J Neuroimmunol 2011;237:98-100.

e8. Harding K, Ingram G, Cossburn M, et al. Genotype-phenotype correlation for non-HLA disease associated risk alleles in multiple sclerosis. Neurosci Lett 2012;526:15-19.

e9. Ebers GC. Natural history of primary progressive multiple sclerosis. Mult Scler 2004;10 Suppl 1:S8-13; discussion S13-15.

e10. Kuchling J, Ramien C, Bozin I, et al. Identical lesion morphology in primary progressive and relapsing-remitting MS--an ultrahigh field MRI study. Mult Scler 2014;20:1866-1871.

e11. Orbach R, Zhao Z, Wang YC, O'Neill G, Cadavid D. Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials. PLoS One 2012;7:e45409.

e12. Lassmann H. New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep 2007;7:239-244.

e13. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012;8:647-656.

e14. Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol 2019;9.

e15. Sotirchos ES, et al. Progressive multiple sclerosis is associated with faster and specific retinal layer atrophy. Ann Neurol 2020;87:885-896.

e16. Jankowska-Lech I, et al. Peripapillary retinal nerve fiber layer thickness measured by optical coherence tomography in different clinical subtypes of multiple sclerosis. Mult Scler Relat Disord 2019;27:260-268.

e17. Oberwahrenbrock T, et al. Retinal Damage in Multiple Sclerosis Disease Subtypes Measured by High-Resolution Optical Coherence Tomography. Mult Scler Int 2012;2012:530305.

e18. Popescu BF, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol 2012;7:185-217.

e19. Tremlett H, Zhao Y, Joseph J, Devonshire V, Neurologists UC. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry 2008;79:1368-1374.

e20. Fransen NL, et al. Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions. Brain 2020;143(6):1714-1730.

e21. Machado-Santos J, et al. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain 2018;141(7):2066-2082.

e22. Smolders J , et al. Perivascular tissue resident memory T cells as therapeutic target in multiple sclerosis. Expert Rev Neurother 2020;1-14.

e23. Elliott C, et al. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain 2019;142(9):2787-2799.

e24. Elliott C, et al. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Mult Scler 2019;25(14):1915-1925.

e25. Martin SJ, et al. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies. J Neurol Neurosurg Psychiatry 2019;90(9):1059-1067.

e26. Bridel C, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol 2019;76(9):1035-1048.

e27. Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 2014;85:67-75.

e28. Zeydan B, Kantarci OH. Progressive forms of multiple sclerosis: distinct entity or age-dependent phenomena. Neurol Clin 2018;36:163-171

e29. Chard DT, Griffin CM, Parker GJM, Kapoor R, Thompson AJ, Miller DH. Brain atrophy in clinically early relapsing–remitting multiple sclerosis. Brain 2002;125:327-337.

e30. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 2012;11:1006-1012.

e31. Bigler ED, Stern Y. Traumatic brain injury and reserve. Handb Clin Neurol 2015;128:691-710.

e32. Sumowski JF, et al. Brain reserve and cognitive reserve in multiple sclerosis: what you've got and how you use it. Neurology 2013;80(24):2186-93.

e33. Sumowski JF, et al. Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. Neurology 2014;82(20):1776-83.

e.34. Sumowski JF, et al. Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis Neurology 2010;74(24):1942-5.

e35. Sumowski JF, Leavitt VM. Cognitive reserve in multiple sclerosis. Mult Scler. 2013; 19(9):1122-7. E35

e36. Schwartz CE, et al. Cognitive reserve and patient-reported outcomes in multiple sclerosis. Mult Scler 2013;19(1):87-105.

e37. Marrie RA et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010; 74:1041–7.

e38. Klaren RE, Hubbard EA, Motl RW, Pilutti LA, Wetter NC, Sutton BP. Objectively measured physical activity is associated with brain volumetric measurements in multiple sclerosis. Behav Neurol 2015;2015:482536.

e39. Schwartz CE, Ayandeh A, Ramanathan M, et al. Reserve-building activities in multiple sclerosis patients and healthy controls: a descriptive study. BMC Neurol 2015;15:135.

e40. Australian Government: Department of Health Therapeutic Goods Administration: Australian prescription medicine decision summaries - Ocrevus. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2017-PI-02089-1> (2017). Accessed October 05 2020.

e41. European Medicines Agency: Ocrevus: EPAR - Product information. <https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information_en.pdf> (2018). Accessed October 05 2020.

e42. Genentech USA, Inc.: Ocrevus – prescribing information. <https://www.gene.com/download/pdf/ocrevus_prescribing.pdf> (2017). Accessed October 05 2020.

e43. European Medicines Agency: Mayzent: EPAR - Product information. <https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_en.pdf> (2020). Accessed October 05 2020.

e44. Novartis Pharmaceuticals Corporation: Mayzent® – prescribing information. <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/mayzent.pdf> (2019). Accessed October 05 2020.

e45. Australian Government: Department of Health Therapeutic Goods Administration: Australian prescription medicine decision summaries - Mayzent. <https://www.tga.gov.au/apm-summary/mayzent> (2019). Accessed October 05 2020.

e46. Novartis Pharma KK: Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options. <https://www.novartis.com/news/media-releases/novartis-receives-simultaneous-approval-five-new-products-from-japanese-ministry-health-labour-and-welfare-offering-japanese-patients-broad-range-novel> (2020). Accessed October 05 2020.

e47. EMD Serono: Mavenclad – prescribing information. <https://www.emdserono.com/us-en/pi/mavenclad-pi.pdf> (2019). Accessed October 05 2020.

e48. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162-173.

e49. Hunter SF, Bowen JD, Reder AT. The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis. CNS Drugs 2016;30:135-147.